vericel
announces
preliminary
third
quarter
total
net
revenues
million
revenue
implant
biopsy
growth
maci
quarter
record
monthly
biopsies
september
approximately
million
operating
cash
flow
quarter
cambridge
globe
newswire
vericel
corporation
nasdaq
vcel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
today
announced
preliminary
financial
results
quarter
ended
september
preliminary
total
net
revenues
third
quarter
expected
approximately
million
including
approximately
million
autologous
cultured
chondrocytes
porcine
collagen
membrane
net
revenue
approximately
million
cultured
epidermal
autografts
net
revenue
approximately
million
revenue
related
procurement
concentrate
proteolytic
enzymes
enriched
bromelain
biomedical
advanced
research
development
authority
barda
emergency
response
preparedness
company
generated
approximately
million
operating
cash
flow
third
quarter
september
company
approximately
million
cash
investments
debt
compared
million
december
pleased
third
quarter
results
generated
consistent
growth
revenue
implants
biopsies
maci
achieved
record
monthly
high
biopsies
september
said
nick
colangelo
president
ceo
vericel
moreover
robustness
business
model
demonstrated
generated
positive
operating
cash
flow
quarter
considerable
uncertainties
related
remain
given
strength
patient
pipeline
expect
maintain
strong
maci
growth
fourth
quarter
look
forward
providing
updates
investors
upcoming
virtual
analyst
investor
day
webcast
third
quarter
earnings
previously
announced
company
host
virtual
analyst
investor
day
october
eastern
time
company
also
host
webcast
conference
call
discuss
third
quarter
financial
results
business
highlights
november
eastern
time
webcast
information
found
events
presentation
section
investor
relations
website
https
vericel
corporation
vericel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
company
markets
two
cell
therapy
products
united
states
maci
autologous
cultured
chondrocytes
porcine
collagen
membrane
autologous
cellularized
scaffold
product
indicated
repair
symptomatic
single
multiple
cartilage
defects
knee
without
bone
involvement
adults
epicel
cultured
epidermal
autografts
permanent
skin
replacement
treatment
patients
deep
dermal
burns
greater
equal
total
body
surface
area
company
also
holds
exclusive
license
north
american
commercial
rights
nexobrid
biological
orphan
product
debridement
severe
thermal
burns
information
please
visit
company
website
registered
trademarks
vericel
corporation
registered
trademark
mediwound
used
license
vericel
corporation
vericel
corporation
rights
reserved
preliminary
unaudited
nature
reported
results
revenue
expectations
third
quarter
well
estimates
concerning
operating
cash
flow
cash
investments
preliminary
unaudited
subject
adjustment
course
ongoing
internal
control
review
procedures
statements
vericel
cautions
statements
statements
historical
fact
included
press
release
address
activities
events
developments
expect
believe
anticipate
may
occur
future
statements
although
believe
reasonable
basis
statements
contained
herein
based
current
expectations
future
events
affecting
us
subject
risks
assumptions
uncertainties
factors
relating
operations
business
environment
difficult
predict
many
beyond
control
actual
results
may
differ
materially
expressed
implied
statements
press
release
statements
often
always
made
use
words
phrases
anticipates
intends
estimates
plans
expects
continues
believe
guidance
outlook
target
future
potential
goals
similar
words
phrases
future
conditional
verbs
would
could
may
similar
expressions
among
factors
may
result
differences
inherent
uncertainties
associated
expectations
concerning
expected
revenue
results
third
quarter
estimates
operating
cash
flow
cash
investments
september
vericel
revenue
expectations
operating
cash
flow
third
quarter
well
estimates
concerning
cash
investments
preliminary
unaudited
subject
adjustment
ongoing
internal
review
additional
factors
could
cause
actual
results
differ
materially
set
forth
statements
include
limited
uncertainties
associated
expectations
regarding
future
revenues
growth
revenues
market
penetration
maci
epicel
growth
profit
gross
margins
operating
margins
ability
achieve
sustain
profitability
contributions
adjusted
ebitda
expected
target
surgeon
audience
potential
fluctuations
sales
volumes
results
operations
course
year
competitive
developments
changes
third
party
coverage
reimbursement
ability
supply
meet
customer
demand
products
impacts
pandemic
business
economy
generally
respect
currently
unable
reasonably
estimate
specific
extent
duration
impact
outbreak
business
financial
operating
results
also
unable
predict
outbreak
affect
pace
state
local
governments
lift
restrictions
performance
elective
surgical
procedures
whether
additional
restrictions
may
imposed
states
future
availability
physicians
treatment
prioritizations
impact
outbreak
overall
healthcare
infrastructure
disruptions
potential
disruptions
include
restrictions
ability
company
personnel
travel
access
customers
training
promotion
case
support
delays
product
development
efforts
additional
quarantines
requirements
shelter
home
incremental
mitigation
efforts
may
impact
ability
source
supplies
operations
ability
capacity
manufacture
sell
support
use
products
respect
fda
review
pending
nexobrid
biologics
license
application
pandemic
may
impact
fda
response
time
regulatory
submissions
ability
monitor
clinical
trials
conduct
necessary
reviews
inspections
may
result
timelines
materially
delayed
could
affect
development
ultimate
commercialization
nexobrid
total
impact
disruptions
could
material
impact
company
financial
condition
cash
flows
results
operations
significant
factors
discussed
greater
detail
vericel
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
february
vericel
quarterly
report
form
quarter
ended
june
filed
sec
august
filings
sec
statements
reflect
views
date
hereof
vericel
assume
specifically
disclaims
obligation
update
statements
reflect
change
views
events
circumstances
occur
date
release
except
required
law
investor
contacts
lee
stern
solebury
trout
lstern
